Evidence map›Paper›PMID 39507023›Full record

ArticleTranslational lung cancer research2024

Inflammation, tertiary lymphoid structures, and lung cancer: a bibliometric analysis.

Xiwen Liu, Huiting Liu, Linchong Huang, Lixuan Lin, Qi Cai, Yang Xiang, Zengfu Liu, Shuxin Zeng, Jianxing He, Wenhua Liang

Abstract read
In one paragraph

Article in Translational lung cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiwen Liu *Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Huiting Liu *Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Linchong Huang *Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Lixuan Lin *Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Qi CaiDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Yang XiangDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Zengfu LiuThe First Clinical College of Guangzhou Medical University, Guangzhou, China.
Shuxin ZengThe First Clinical College of Guangzhou Medical University, Guangzhou, China.
Jianxing HeDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Wenhua LiangDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The intricate interplay between inflammation and lung cancer has long been recognized by large number of studies, yet a comprehensive understanding of this relationship remains elusive. There is a clinical need to elucidate the role of tertiary lymphoid structures (TLSs) in lung cancer, particularly their impact on prognosis and therapy. This study aims to address these gaps by conducting a bibliometric analysis to explore the correlations between lung cancer, inflammation, and TLS, highlighting collaborative networks, publication trends, and emerging research directions. Methods: This study conducted a comprehensive bibliometric analysis of academic literature on lung cancer and inflammation from 2013 to 2023 using the Web of Science Core Collection database. The search strategy "topic (TS) = ('lung cancer') AND TS = (inflammation)" yielded 5,470 records, which were refined through exclusion criteria to 1,284 relevant studies. The inclusion process involved excluding non-English studies and non-original articles or reviews, followed by a relevance check based on titles and abstracts. The bibliometric indicators were calculated based on a transparent and repeatable methodology to ensure the integrity of the findings. Results: The investigation encompassed 1,284 selected studies, revealing an escalating publication trend since 2013. The interdisciplinary scope of research is apparent, with contributions from 54 countries, with China at the forefront. In-depth author and journal analyses exposed key contributors like Zhang L and influential journals like " Conclusions: This study underscores the pivotal role of inflammation in lung cancer progression, mediated by a delicate balance of immune responses. The emerging prominence of TLS as indicator of adaptive immune responses within the tumor microenvironment (TME) offers intriguing avenues for future research and therapeutic interventions. However, limitations in the current research, such as the need for more longitudinal studies and clinical trials, must be addressed. The insights gained from this bibliometric analysis can inform clinical practices and guide future investigations into novel strategies to improve patient outcomes.

Indexed as

immune responseInflammationlung cancermicroenvironmenttertiary lymphoid structures (TLSs)

Identifiers

PMID39507023
PMCPMC11535850

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.